Credit Suisse Group set a €71.00 ($82.56) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note published on Thursday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Other research analysts have also issued research reports about the stock. Independent Research set a €74.00 ($86.05) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a report on Monday, June 17th. HSBC set a €101.00 ($117.44) target price on shares of Grenke and gave the company a buy rating in a research report on Thursday, April 25th. Morgan Stanley increased their target price on shares of WPP from GBX 1,025 ($13.39) to GBX 1,060 ($13.85) and gave the company an equal weight rating in a research report on Wednesday, July 17th. Deutsche Bank set a €230.00 ($267.44) target price on shares of adidas and gave the company a neutral rating in a research report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of SUZUKI MTR CORP/ADR in a research report on Wednesday, July 17th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of €82.57 ($96.01).
Shares of ETR FME opened at €67.00 ($77.91) on Thursday. The firm has a 50 day simple moving average of €68.38. The company has a market cap of $20.45 billion and a price-to-earnings ratio of 10.43. Fresenius Medical Care AG & Co. KGaA has a 1 year low of €55.44 ($64.47) and a 1 year high of €91.74 ($106.67). The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of 100.05.
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Article: Commodities
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.